Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis

Canadian Journal of Cardiology

Volumn 22, Issue 3, 2006, Pages 263-266

  Bar, Simona L ^a   Swiggum, Elizabeth ^a   Straatman, Lynn ^a   Ignaszewski, Andrew ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

Congestive heart failure; Natriuretic peptides; Shock

Indexed keywords

ANTIBIOTIC AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; FUROSEMIDE; INOTROPIC AGENT; METOLAZONE; NORADRENALIN; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; ASPIRATION PNEUMONIA; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIAGNOSTIC ERROR; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART VALVE REPLACEMENT; HUMAN; LEUKOCYTE COUNT; LUNG CAPILLARY PRESSURE; MALE; MITRAL VALVE REGURGITATION; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; REOPERATION; SEPSIS; SEPTIC SHOCK; SERRATIA; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; FATALITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FATAL OUTCOME; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SEPSIS;

EID: 33645765802     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70908-4     Document Type: Letter

References (39)

1. Waisbren BA. Bacteremia due to Gram-negative bacilli other than the Salmonella: A clinical and therapeutic study. AMA Arch Internal Med 1951;88:467-88.
2. Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32:660-5.
3. de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004;43:1584-9.
4. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
5. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
6. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-44.
7. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: A brief review. Clin Exp Pharmacol Physiol 2004;31:791-4.
8. Peacock WF IV. The B-type natriuretic peptide assay: A rapid test for heart failure. Cleve Clin J Med 2002;69:243-51.
9. Castillo JR, Zagler A, Carillo-Jimenez R, Hennekens CH. Brain natriuretic peptide: A potential marker for mortality in septic shock. Int J Infect Dis 2004;8:271-4.
10. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993;132:1961-70.
11. Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989;159:1427-34.
12. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to aminoterminal BNP and BNP-32. Peptides 1997;18:1475-81.
13. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;4(Suppl 4):S13-9.
14. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-96.
15. Baggish AL, Cameron R, Anwaruddin S, et al. A Clinical and Biochemical Critical Pathway for the Evaluation of Patients with Suspected Acute Congestive Heart Failure. The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Algorithm. Crit Pathways in Cardiol 2004;3:171-6.
16. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
17. Maisel AS, Clopton P, Krishnaswamy F, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:1078-84.
18. Bay M, Kirk V, Parner J, et al. NT-proBNP: A new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
19. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
20. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990;97:126-31.
21. Chua G, Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004;8:R248-50.
22. Fitch SJ, Gossage JR. Optimal management of septic shock: Rapid recognition and institution of therapy are crucial. Postgrad Med 2002;111:53-66.
23. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-90.
24. Jafti SM, Lavine S, Field BE, Baharozian MT, Carlson RW. Left ventricutar diastolic function in sepsis. Crit Care Med 1990;18:709-14.
25. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-58.
26. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003;29:1696-702.
27. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004;36:505-13.
28. Hamanaka I, Saito Y, Nishikimi T, et al. Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. Am J Physiol Heart Circ Physiol 2000;279:H388-96.
29. van der Zander K, Houben AJ, Kroon AA, De Mey JG, Smits PA, de Leeuw PW. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens 2002;20:493-9.
30. Ishibashi Y, Shimada T, Sakane T, et al. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart. J Am Coll Cardiol 2000;36:1605-11.
31. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000;161:1781-5.
32. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: Importance of cyclic GMP. Diabetes 2003;52:2389-95.
33. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 1998;275:H1016-23.
34. Sibelius U, Grandel U, Buerke M, et al. Staphylococcal alpha-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts: Role of thromboxane generation. Circulation 2000;101:78-85.
35. Witthaut R. Science review: Natriuretic peptides in critical illness. Crit Care 2004;8:342-9.
36. Wray GM, Foster SJ, Hinds Q, Thiemermann C. A cell wall component from pathogenic and non-pathogenic Gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock 2001;15:135-42.
37. Ravichandran LV, Johns RA, Rengasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol 1995;268:H2216-23.
38. Grandel U, Sibelius U, Schrickel J, et al. Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med 2001;29:1-7.
39. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-22.